FRI0315 Safety, tolerability, pharmacokinetic and pharmacodynamic effects of biib059, a monoclonal antibody targeting bdca2 following intravenous (IV) and subcutaneous (SC) single or multiple doses administration in healthy volounteers (HV) and subjects with active systemic lupus erythematosus (SLE)

Abstract

BackgroundBDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, upon activation, inhibits the inflammatory factors production by human pDCs, including IFN-α a major player in the pathogenesis of SLE. This...